Published in Br J Haematol on May 09, 2010
Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma (2011) 1.54
Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett (2011) 1.21
Curcumin nanodisks: formulation and characterization. Nanomedicine (2010) 1.12
Nanobiotechnology applications of reconstituted high density lipoprotein. J Nanobiotechnology (2010) 0.97
Novel therapies for aggressive B-cell lymphoma. Adv Hematol (2012) 0.94
Vaults engineered for hydrophobic drug delivery. Small (2011) 0.93
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat Res (2015) 0.84
NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Int J Nanomedicine (2013) 0.80
Cationic lipid nanodisks as an siRNA delivery vehicle. Biochem Cell Biol (2014) 0.80
Strategies on the nuclear-targeted delivery of genes. J Drug Target (2013) 0.78
Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles. J Anal Oncol (2012) 0.76
Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. Biochem Cell Biol (2015) 0.76
High-Density Lipoproteins for Therapeutic Delivery Systems. J Mater Chem B Mater Biol Med (2015) 0.75
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging. Curr Med Chem (2015) 0.75
Use of single chain antibody derivatives for targeted drug delivery. Mol Med (2016) 0.75
Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. Int J Nanomedicine (2016) 0.75
Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. Int J Nanomedicine (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Mitochondria and apoptosis. Science (1998) 23.41
RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov (2007) 3.07
The promise of retinoids to fight against cancer. Nat Rev Cancer (2001) 2.92
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood (2005) 2.19
Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif (2003) 2.13
Retinoic acid receptors and cancers. Annu Rev Nutr (2004) 1.93
Retinoids selective for retinoid X receptor response pathways. Science (1992) 1.91
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.81
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica (2009) 1.79
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma (2006) 1.60
Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med (2003) 1.52
Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia (2008) 1.45
Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem (1999) 1.36
Nanodisks: hydrophobic drug delivery vehicles. Expert Opin Drug Deliv (2008) 1.31
Cell-cycle control in the face of damage--a matter of life or death. Trends Cell Biol (2009) 1.30
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood (2001) 1.27
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood (2000) 1.25
G0S2 is an all-trans-retinoic acid target gene. Int J Oncol (2008) 1.23
All-trans-retinoic acid nanodisks. Int J Pharm (2007) 1.23
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood (2004) 1.23
p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer. J Biol Chem (2007) 1.11
The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol (2007) 1.10
Dominant negative retinoid X receptor beta inhibits retinoic acid-responsive gene regulation in embryonal carcinoma cells. Mol Cell Biol (1994) 1.09
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res (2000) 1.07
Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem (2003) 1.06
Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol (2000) 1.03
Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid-resistant human breast cancer cells. J Biol Chem (1997) 0.96
Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis (1997) 0.94
Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth Differ (2000) 0.94
Targeting nanodisks via a single chain variable antibody--apolipoprotein chimera. Biochem Biophys Res Commun (2008) 0.93
All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. Oncologist (1996) 0.93
bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol (1996) 0.92
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res (2003) 0.92
Retinoic-acid-induced apoptosis in leukemia cells. Trends Mol Med (2004) 0.88
Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res (2005) 0.87
Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ (1997) 0.86
p21 is required for atRA-mediated growth inhibition of MEPM cells, which involves RAR. J Cell Biochem (2008) 0.83
Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines. Int J Cancer (2000) 0.81
Expression of nuclear retinoic acid receptor in peripheral blood mononuclear cells (PBMC) of healthy subjects. Life Sci (2003) 0.80
Retinoids and cancer: antitumoral effects of ATRA, 9-cis RA and the new retinoid IIF on the HL-60 leukemic cell line. Med Princ Pract (2003) 0.80
Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells. Clin Cancer Res (2001) 0.79
Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7. J Cell Biochem (2006) 0.79
Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. Arch Pathol Lab Med (2000) 0.78
Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell leukemia cells. Clin Cancer Res (1999) 0.77
Cyclin D1 protein expression in mantle cell lymphoma. Ann Oncol (1995) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol (2009) 3.07
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol (2006) 2.92
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park) (2010) 2.41
Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm (2006) 2.34
Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia. Am J Clin Pathol (2011) 2.18
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif (2003) 2.13
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell (2003) 2.05
Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol (2005) 1.97
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem (2008) 1.91
Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma (2006) 1.89
Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81
Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein. J Biol Chem (2006) 1.79
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol (2007) 1.72
Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71
AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther (2010) 1.66
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res (2010) 1.63
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
The C-terminal domain of apolipoprotein A-I contains a lipid-sensitive conformational trigger. Nat Struct Biol (2003) 1.61
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA (2006) 1.59
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol (2007) 1.58
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol (2012) 1.56
Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56
Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem (2005) 1.55
Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma (2011) 1.54
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma (2009) 1.53
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
T-cell non-Hodgkin lymphoma. Blood (2005) 1.53
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol (2003) 1.52
Jak family of kinases in cancer. Cancer Metastasis Rev (2003) 1.52
Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res (2005) 1.52
Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci (2006) 1.52
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood (2012) 1.49
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2002) 1.47
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol (2008) 1.44
Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies. Oncology (Williston Park) (2015) 1.44
Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol (2002) 1.41
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer (2007) 1.41
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.40
Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res (2005) 1.40
Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution. Biochim Biophys Acta (2007) 1.39
Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep (2010) 1.38
Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res (2006) 1.36
Statins in tumor suppression. Cancer Lett (2008) 1.34
Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene (2002) 1.32
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem (2004) 1.29
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 1.29
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.28
Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther (2008) 1.28
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol (2012) 1.28
Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem (2003) 1.27
Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry (2007) 1.26